

The format and content in this table has not been edited by ActaDV.

Table SIV. Treatment of patients with metastatic cutaneous squamous cell carcinomas (mcSCC)

Treatment modalities of mcSCCs	Total	Male	Female	P value
Primary tumor, n	85	57	28	
Resection, n (%)	81 (95.3)	54 (94.7)	27 (96.4)	>.99
Radiation therapy, n (%)	31 (36.5)	23 (40.4)	8 (28.6)	.29
Radiation therapy alone, n (% of total)	1 (1.2)	0 (0.0)	1 (3.6)	
Curation aimed, n (% of radiated)	28 (90.3)	22 (95.7)	6 (75.0)	.16
Palliative, n (% of radiated)	3 (9.7)	1 (4.3)	2 (25.0)	.16
No treatment, n (%)	3 (3.5)	3 (5.3)	0 (0.0)	
Perioperative exitus, n (% of no treatment)	1 (33.3)	1 (33.3)	0 (0.0)	
Metastasis, n	85	57	28	
Resection, n (%)	78 (91.8)	52 (91.2)	26 (92.9)	>.99
Radiation therapy, n (%)	55 (64.9)	39 (68.4)	16 (57.1)	.31
Radiation therapy alone, n (%)	2 (2.6)	1 (1.8)	1 (3.6)	
Curation aimed, n (% of radiated)	43 (78.2)	33 (84.6)	10 (62.5)	.09
Palliative, n (% of radiated)	12 (21.8)	6 (15.4)	6 (37.5)	.09
Only systemic treatment, n (%)	1 (1.2)	1 (1.8)	0 (0.0)	
No treatment, n (%)	4 (4.7)	3 (5.3)	1 (3.6)	
Perioperative exitus, n (% of no treatment)	2 (50.0)	2 (66.7)	0 (0.0)	
Systemic treatment, n (%)	11 (12.9)	10 (17.5)	1 (3.6)	.09
Systemic treatment alone, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	
Pharmaceutical used				
Cisplatin, n (% of systemic treatment)	6 (54.5)	5 (50.0)	1 (100.0)	>.99
Fluorouracil, n (% of systemic treatment)	1 (9.1)	1 (10.0)	0 (0.0)	>.99
Paclitaxel, n (% of systemic treatment)	2 (18.2)	2 (20.0)	0 (0.0)	>.99
Cetuximab, n (% of systemic treatment)	5 (45.5)	5 (50.0)	0 (0.0)	>.99
Cemiplimab, n (% of systemic treatment)	2 (18.2)	2 (20.0)	0 (0.0)	>.99